249 related articles for article (PubMed ID: 34083490)
1. Antibody fucosylation predicts disease severity in secondary dengue infection.
Bournazos S; Vo HTM; Duong V; Auerswald H; Ly S; Sakuntabhai A; Dussart P; Cantaert T; Ravetch JV
Science; 2021 Jun; 372(6546):1102-1105. PubMed ID: 34083490
[TBL] [Abstract][Full Text] [Related]
2. Antibody with an engineered Fc region as a therapeutic agent against dengue virus infection.
Ramadhany R; Hirai I; Sasaki T; Ono K; Ramasoota P; Ikuta K; Kurosu T
Antiviral Res; 2015 Dec; 124():61-8. PubMed ID: 26522769
[TBL] [Abstract][Full Text] [Related]
3. Modulation of Dengue/Zika Virus Pathogenicity by Antibody-Dependent Enhancement and Strategies to Protect Against Enhancement in Zika Virus Infection.
Khandia R; Munjal A; Dhama K; Karthik K; Tiwari R; Malik YS; Singh RK; Chaicumpa W
Front Immunol; 2018; 9():597. PubMed ID: 29740424
[TBL] [Abstract][Full Text] [Related]
4. Zika convalescent macaques display delayed induction of anamnestic cross-neutralizing antibody responses after dengue infection.
Valiant WG; Huang YS; Vanlandingham DL; Higgs S; Lewis MG; Mattapallil JJ
Emerg Microbes Infect; 2018 Jul; 7(1):130. PubMed ID: 30006514
[TBL] [Abstract][Full Text] [Related]
5. IgG antibodies to dengue enhanced for FcγRIIIA binding determine disease severity.
Wang TT; Sewatanon J; Memoli MJ; Wrammert J; Bournazos S; Bhaumik SK; Pinsky BA; Chokephaibulkit K; Onlamoon N; Pattanapanyasat K; Taubenberger JK; Ahmed R; Ravetch JV
Science; 2017 Jan; 355(6323):395-398. PubMed ID: 28126818
[TBL] [Abstract][Full Text] [Related]
6. Maternally Acquired Zika Antibodies Enhance Dengue Disease Severity in Mice.
Fowler AM; Tang WW; Young MP; Mamidi A; Viramontes KM; McCauley MD; Carlin AF; Schooley RT; Swanstrom J; Baric RS; Govero J; Diamond MS; Shresta S
Cell Host Microbe; 2018 Nov; 24(5):743-750.e5. PubMed ID: 30439343
[TBL] [Abstract][Full Text] [Related]
7. Complexity of Neutralizing Antibodies against Multiple Dengue Virus Serotypes after Heterotypic Immunization and Secondary Infection Revealed by In-Depth Analysis of Cross-Reactive Antibodies.
Tsai WY; Durbin A; Tsai JJ; Hsieh SC; Whitehead S; Wang WK
J Virol; 2015 Jul; 89(14):7348-62. PubMed ID: 25972550
[TBL] [Abstract][Full Text] [Related]
8. Dengue virus neutralization and antibody-dependent enhancement activities of human monoclonal antibodies derived from dengue patients at acute phase of secondary infection.
Sasaki T; Setthapramote C; Kurosu T; Nishimura M; Asai A; Omokoko MD; Pipattanaboon C; Pitaksajjakul P; Limkittikul K; Subchareon A; Chaichana P; Okabayashi T; Hirai I; Leaungwutiwong P; Misaki R; Fujiyama K; Ono K; Okuno Y; Ramasoota P; Ikuta K
Antiviral Res; 2013 Jun; 98(3):423-31. PubMed ID: 23545366
[TBL] [Abstract][Full Text] [Related]
9. A prospective nested case-control study of Dengue in infants: rethinking and refining the antibody-dependent enhancement dengue hemorrhagic fever model.
Libraty DH; Acosta LP; Tallo V; Segubre-Mercado E; Bautista A; Potts JA; Jarman RG; Yoon IK; Gibbons RV; Brion JD; Capeding RZ
PLoS Med; 2009 Oct; 6(10):e1000171. PubMed ID: 19859541
[TBL] [Abstract][Full Text] [Related]
10. Cross-Reactive Dengue Virus Antibodies Augment Zika Virus Infection of Human Placental Macrophages.
Zimmerman MG; Quicke KM; O'Neal JT; Arora N; Machiah D; Priyamvada L; Kauffman RC; Register E; Adekunle O; Swieboda D; Johnson EL; Cordes S; Haddad L; Chakraborty R; Coyne CB; Wrammert J; Suthar MS
Cell Host Microbe; 2018 Nov; 24(5):731-742.e6. PubMed ID: 30439342
[TBL] [Abstract][Full Text] [Related]
11. Antibody avidity following secondary dengue virus type 2 infection across a range of disease severity.
Lau L; Green AM; Balmaseda A; Harris E
J Clin Virol; 2015 Aug; 69():63-7. PubMed ID: 26209381
[TBL] [Abstract][Full Text] [Related]
12. Monomeric IgA Antagonizes IgG-Mediated Enhancement of DENV Infection.
Wegman AD; Fang H; Rothman AL; Thomas SJ; Endy TP; McCracken MK; Currier JR; Friberg H; Gromowski GD; Waickman AT
Front Immunol; 2021; 12():777672. PubMed ID: 34899736
[TBL] [Abstract][Full Text] [Related]
13. High frequency of pre-existing neutralizing antibody responses in patients with dengue during an outbreak in Central Brazil.
de Teive E Argolo AF; de Rezende Féres VC; Cordeiro MT; da Silveira LA; Guilarde AO; de Azevedo Marques ET; de Souza WV; Martelli CM
BMC Infect Dis; 2016 Oct; 16(1):546. PubMed ID: 27717314
[TBL] [Abstract][Full Text] [Related]
14. Low levels of antibody-dependent enhancement in vitro using viruses and plasma from dengue patients.
Chaichana P; Okabayashi T; Puiprom O; Sasayama M; Sasaki T; Yamashita A; Ramasoota P; Kurosu T; Ikuta K
PLoS One; 2014; 9(3):e92173. PubMed ID: 24642752
[TBL] [Abstract][Full Text] [Related]
15. Dengue virus infection-enhancing activity of undiluted sera obtained from patients with secondary dengue virus infection.
Moi ML; Takasaki T; Saijo M; Kurane I
Trans R Soc Trop Med Hyg; 2013 Jan; 107(1):51-8. PubMed ID: 23296697
[TBL] [Abstract][Full Text] [Related]
16. Dengue virus infection-enhancing and neutralizing antibody balance in children of the Philippines and Indonesia.
Yamanaka A; Tabuchi Y; Mulyatno KC; Susilowati H; Hendrianto E; Soegijanto S; Konishi E
Microbes Infect; 2012 Nov; 14(13):1152-9. PubMed ID: 22841680
[TBL] [Abstract][Full Text] [Related]
17. Identification of chimpanzee Fab fragments by repertoire cloning and production of a full-length humanized immunoglobulin G1 antibody that is highly efficient for neutralization of dengue type 4 virus.
Men R; Yamashiro T; Goncalvez AP; Wernly C; Schofield DJ; Emerson SU; Purcell RH; Lai CJ
J Virol; 2004 May; 78(9):4665-74. PubMed ID: 15078949
[TBL] [Abstract][Full Text] [Related]
18. Dengue Virus and Zika Virus Serological Cross-reactivity and Their Impact on Pathogenesis in Mice.
Watanabe S; Tan NWW; Chan KWK; Vasudevan SG
J Infect Dis; 2019 Jan; 219(2):223-233. PubMed ID: 30085051
[TBL] [Abstract][Full Text] [Related]
19. A plant-produced vaccine protects mice against lethal West Nile virus infection without enhancing Zika or dengue virus infectivity.
Lai H; Paul AM; Sun H; He J; Yang M; Bai F; Chen Q
Vaccine; 2018 Mar; 36(14):1846-1852. PubMed ID: 29490880
[TBL] [Abstract][Full Text] [Related]
20. Dengue virus infection-enhancement activity in neutralizing antibodies of healthy adults before dengue season as determined by using FcγR-expressing cells.
Ly MHP; Moi ML; Vu TBH; Tun MMN; Saunders T; Nguyen CN; Nguyen AKT; Nguyen HM; Dao TH; Pham DQ; Nguyen TTT; Le TQM; Hasebe F; Morita K
BMC Infect Dis; 2018 Jan; 18(1):31. PubMed ID: 29321001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
